Showing results (1911-1920 of 1,974) with videos related to
Sort By:
Pageof 198
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2019
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell CarcinomaDaniel J Ma, Katharine A Price, Eric J Moore, et al.Npj Aging|August 4, 2022
Age-dependent impact of two exercise training regimens on genomic and metabolic remodeling in skeletal muscle and liver of male miceMichel Bernier, Ignacio Navas Enamorado, Mari Carmen Gómez-Cabrera, et al.Nature Genetics|May 22, 2012
Extremely low-coverage sequencing and imputation increases power for genome-wide association studiesBogdan Pasaniuc, Nadin Rohland, Paul J McLaren, et al.Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.Nature Genetics|January 20, 2009
A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South AsiaPerundurai S Dhandapany, Sakthivel Sadayappan, Yali Xue, et al.Nature Aging|January 12, 2026
Senotoxins target senescence via lipid binding specificity, ion imbalance and lipidome remodelingJavier Moral-Sanz, Isabel Fernández-Carrasco, Valentina Ramponi, et al.JCI Insight|January 10, 2023
microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosisFarida Ahangari, Nathan L Price, Shipra Malik, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancerMelanie Royce, Mirat Shah, Lijun Zhang, et al.Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.Cell Metabolism|September 11, 2021
Fasting blood glucose as a predictor of mortality: Lost in translationDushani L Palliyaguru, Eric J Shiroma, John K Nam, et al.Pageof 198